REFERENCES
1. Bozkurt B, Coats AJ, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the heart failure society of america, heart failure association of the european society of cardiology, japanese heart failure society and writing committee of the universal definition of heart failure. J Card Fail. 2021;27:387-413.
2. Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2022;118:3272-87.
3. Emmons-Bell S, Johnson C, Roth G. Prevalence, incidence and survival of heart failure: a systematic review. Heart. 2022;108:1351-60.
4. Lin Q, Lv Z, Li D, et al. Heart failure medication treatment and prognosis: a retrospective cross-sectional study. Front. Pharmacol. 2025;16:1532123.
5. Brown DA, Perry JB, Allen ME, et al. Expert consensus document: mitochondrial function as a therapeutic target in heart failure. Nat Rev Cardiol. 2016;14:238-50.
7. Alcaide P, Kallikourdis M, Emig R, Prabhu SD. Myocardial inflammation in heart failure with reduced and preserved ejection fraction. Circ Res. 2024;134:1752-66.
8. Tsigkou V, Oikonomou E, Anastasiou A, et al. Molecular mechanisms and therapeutic implications of endothelial dysfunction in patients with heart failure. Int J Mol Sci. 2023;24:4321.
9. González A, Schelbert EB, Díez J, Butler J. Myocardial interstitial fibrosis in heart failure: biological and translational perspectives. J Am Coll Cardiol. 2018;71:1696-706.
10. Vishnoi A, Rani S. MiRNA biogenesis and regulation of diseases: an overview. Methods Mol Biol. 2017;1509:1-10.
12. Alaei A, Kakumani PK. MicroRNA chemical modifications in post-transcriptional gene silencing and human diseases. Mol Ther Nucleic Acids. 2025;36:102745.
13. Ao X, Ding W, Li X, et al. Non-coding RNAs regulating mitochondrial function in cardiovascular diseases. J Mol Med. 2023;101:501-26.
14. Zhang G, Wang S, Chen Y, et al. MicroRNAs regulating mitochondrial function in cardiac diseases. Front Pharmacol. 2021;12:663322.
15. Klimczak-Tomaniak D, Haponiuk-Skwarlińska J, Kuch M, Pączek L. Crosstalk between microRNA and oxidative stress in heart failure: a systematic review. Int J Mol Sci. 2022;23:15013.
16. Qian L, Zhao Q, Yu P, et al. Diagnostic potential of a circulating miRNA model associated with therapeutic effect in heart failure. J Transl Med. 2022;20:267.
17. Maciejak A, Kostarska-srokosz E, Gierlak W, et al. Circulating miR-30a-5p as a prognostic biomarker of left ventricular dysfunction after acute myocardial infarction. Sci Rep. 2018;8:9883.
18. Lopaschuk GD, Karwi QG, Tian R, Wende AR, Abel ED. Cardiac energy metabolism in heart failure. Circ Res. 2021;128:1487-513.
19. Pham T, Loiselle D, Power A, Hickey AJR. Mitochondrial inefficiencies and anoxic ATP hydrolysis capacities in diabetic rat heart. Am J Physiol Cell Physiol. 2014;307:C499-507.
20. Sun Q, Karwi QG, Wong N, Lopaschuk GD. Advances in myocardial energy metabolism: metabolic remodelling in heart failure and beyond. Cardiovasc Res. 2024;120:1996-2016.
21. Mericskay M, Zuurbier CJ, Heather LC, et al. Cardiac intermediary metabolism in heart failure: substrate use, signalling roles and therapeutic targets. Nat Rev Cardiol. 2025;22:704-27.
22. Zhang X, Ji R, Liao X, et al. MicroRNA-195 regulates metabolism in failing myocardium via alterations in sirtuin 3 expression and mitochondrial protein acetylation. Circulation. 2018;137:2052-67.
23. Ding Y, Zhang Y, Lu J, et al. MicroRNA-214 contributes to Ang II-induced cardiac hypertrophy by targeting SIRT3 to provoke mitochondrial malfunction. Acta Pharmacol Sin. 2020;42:1422-36.
24. Larocca TJ, Seeger T, Prado M, et al. Pharmacological silencing of MicroRNA-152 prevents pressure overload-induced heart failure. Circ Heart Failure. 2020;13:e006298.
25. Wu C, Zhang X, Chen L, et al. Pyroptosis and mitochondrial function participated in miR-654-3p-protected against myocardial infarction. Cell Death Dis. 2024;15:393.
26. Song R, Dasgupta C, Mulder C, Zhang L. MicroRNA-210 controls mitochondrial metabolism and protects heart function in myocardial infarction. Circulation. 2022;145:1140-53.
27. Ding H, Wang Y, Hu L, et al. Combined detection of miR-21-5p, miR-30a-3p, miR-30a-5p, miR-155-5p, miR-216a and miR-217 for screening of early heart failure diseases. Biosci Rep. 2020;40:BSR20191653.
28. Dey S, Demazumder D, Sidor A, Foster DB, O’Rourke B. Mitochondrial ROS drive sudden cardiac death and chronic proteome remodeling in heart failure. Circ Res. 2018;123:356-71.
29. Kuka S, Tatarkova Z, Racay P, Lehotsky J, Dobrota D, Kaplan P. Effect of aging on formation of reactive oxygen species by mitochondria of rat heart. Gen Physiol Biophys. 2014;32:415-20.
30. Korge P, John SA, Calmettes G, Weiss JN. Reactive oxygen species production induced by pore opening in cardiac mitochondria: the role of complex II. J Biol Chem. 2017;292:9896-905.
31. Madungwe NB, Zilberstein NF, Feng Y, Bopassa JC. Critical role of mitochondrial ROS is dependent on their site of production on the electron transport chain in ischemic heart. Am J Cardiovasc Dis. 2016;6:93-108.
32. Das S, Bedja D, Campbell N, et al. miR-181c regulates the mitochondrial genome, bioenergetics, and propensity for heart failure in vivo. PLoS ONE. 2014;9:e96820.
33. Yan K, An T, Zhai M, et al. Mitochondrial miR-762 regulates apoptosis and myocardial infarction by impairing ND2. Cell Death Dis. 2019;10:500.
34. Lin B, Feng DG, Xu J. microRNA‐665 silencing improves cardiac function in rats with heart failure through activation of the cAMP signaling pathway. J Cell Physiol. 2019;234:13169-81.
35. Qian L, Zhu Y, Deng C, et al. Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) family in physiological and pathophysiological process and diseases. Sig Transduct Target Ther. 2024;9:50.
36. Li Y, Feng Y, Liu X, et al. Songorine promotes cardiac mitochondrial biogenesis via Nrf2 induction during sepsis. Redox Biol. 2021;38:101771.
37. Whittington HJ, Harding I, Stephenson CI, et al. Cardioprotection in the aging, diabetic heart: the loss of protective Akt signalling. Cardiovasc Res. 2013;99:694-704.
38. Du JK, Cong BH, Yu Q, et al. Upregulation of microRNA-22 contributes to myocardial ischemia-reperfusion injury by interfering with the mitochondrial function. Free Radical Biol Med. 2016;96:406-17.
39. Sun L, Wang N, Ban T, et al. MicroRNA-23a mediates mitochondrial compromise in estrogen deficiency-induced concentric remodeling via targeting PGC-1α. J Mol Cell Cardiol. 2014;75:1-11.
40. Caravia XM, Fanjul V, Oliver E, et al. The microRNA-29/PGC1α regulatory axis is critical for metabolic control of cardiac function. PLoS Biol. 2018;16:e2006247.
41. Chan DC. Mitochondrial dynamics and its involvement in disease. Annu Rev Pathol Mech Dis. 2020;15:235-59.
42. Anand R, Wai T, Baker MJ, et al. The i-AAA protease YME1L and OMA1 cleave OPA1 to balance mitochondrial fusion and fission. J Cell Biol. 2014;204:919-29.
43. Chen L, Gong Q, Stice JP, Knowlton AA. Mitochondrial OPA1, apoptosis, and heart failure. Cardiovasc Res. 2009;84:91-9.
44. Hu L, Ding M, Tang D, et al. Targeting mitochondrial dynamics by regulating Mfn2 for therapeutic intervention in diabetic cardiomyopathy. Theranostics. 2019;9:3687-706.
45. Wang T, Zhai M, Xu S, et al. NFATc3-dependent expression of miR-153-3p promotes mitochondrial fragmentation in cardiac hypertrophy by impairing mitofusin-1 expression. Theranostics. 2020;10:553-66.
46. Shi Y, Zhang Z, Yin Q, et al. Cardiac‐specific overexpression of miR‐122 induces mitochondria‐dependent cardiomyocyte apoptosis and promotes heart failure by inhibiting Hand2. J Cell Mol Med. 2021;25:5326-34.
47. Li J, Li Y, Jiao J, et al. Mitofusin 1 is negatively regulated by MicroRNA 140 in cardiomyocyte apoptosis. Mol Cell Biol. 2023;34:1788-99.
48. Li J, Donath S, Li Y, Qin D, Prabhakar BS, Li P. miR-30 regulates mitochondrial fission through targeting p53 and the dynamin-related protein-1 pathway. PLoS Genet. 2010;6:e1000795.
49. Sotomayor-Flores C, Rivera-Mejías P, Vásquez-Trincado C, et al. Angiotensin-(1-9) prevents cardiomyocyte hypertrophy by controlling mitochondrial dynamics via miR-129-3p/PKIA pathway. Cell Death Differ. 2020;27:2586-604.
50. Wang J, Jiao J, Li Q, et al. miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1. Nat Med. 2010;17:71-8.
51. Wang K, Gan T, Li N, et al. Circular RNA mediates cardiomyocyte death via miRNA-dependent upregulation of MTP18 expression. Cell Death Differ. 2017;24:1111-20.
52. Lin J, Chen K, Chen W, et al. Paradoxical mitophagy regulation by PINK1 and TUFm. Mol Cell. 2020;80:607-20.e12.
53. Liu L, Sakakibara K, Chen Q, Okamoto K. Receptor-mediated mitophagy in yeast and mammalian systems. Cell Res. 2014;24:787-95.
54. Billia F, Hauck L, Konecny F, Rao V, Shen J, Mak TW. PTEN-inducible kinase 1 (PINK1)/Park6 is indispensable for normal heart function. Proc Natl Acad Sci USA. 2011;108:9572-7.
55. Wu S, Lu Q, Wang Q, et al. Binding of FUN14 domain containing 1 with inositol 1,4,5-trisphosphate receptor in mitochondria-associated endoplasmic reticulum membranes maintains mitochondrial dynamics and function in hearts in vivo. Circulation. 2017;136:2248-66.
56. Yan Y, Tian L, Jia Q, et al. MiR-130a-3p regulates FUNDC1-mediated mitophagy by targeting GJA1 in myocardial ischemia/reperfusion injury. Cell Death Discov. 2023;9:77.
57. Gustafsson ÅB, Dorn GW. Evolving and expanding the roles of mitophagy as a homeostatic and pathogenic process. Physiol Rev. 2019;99:853-92.
58. Wang S, Long H, Hou L, et al. The mitophagy pathway and its implications in human diseases. Sig Transduct Target Ther. 2023;8:304.
59. Mu N, Zhang T, Zhu Y, Lu B, Zheng Q, Duan J. The mechanism by which miR-494-3p regulates PGC1-α-mediated inhibition of mitophagy in cardiomyocytes and alleviation of myocardial ischemia—reperfusion injury. BMC Cardiovasc Disord. 2023;23:204.
60. Mckinsey TA, Foo R, Anene-Nzelu CG, et al. Emerging epigenetic therapies of cardiac fibrosis and remodelling in heart failure: from basic mechanisms to early clinical development. Cardiovasc Res. 2022;118:3482-98.
61. Moazzam M, Zhang M, Hussain A, Yu X, Huang J, Huang Y. The landscape of nanoparticle-based siRNA delivery and therapeutic development. Mol Ther. 2024;32:284-312.
62. Yang L, Liu Z, Chen G, et al. MicroRNA-122-mediated liver detargeting enhances the tissue specificity of cardiac genome editing. Circulation. 2024;149:1778-81.
63. Shuvaev VV, Tam YK, Lee BW, et al. Systemic delivery of biotherapeutic RNA to the myocardium transiently modulates cardiac contractility in vivo. Proc Natl Acad Sci USA. 2025;122:e2409266122.
